-
Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains
Monday, April 18, 2016 - 1:03pm | 239Immunomedics, Inc. (NASDAQ: IMMU), a clinical stage biopharmaceutical company that focuses on the treatment of cancer, presented data at the 2016 American Association for Cancer Research's annual meeting. Immunomedics said in a corresponding press release that its presentation focused on...